Encorium Group Inc. is a full-service multinational contract research organization (CRO). They provide design, development, and management capabilities for clinical trials and patient registries. They do this for many of the world’s leading pharmaceutical companies. Trading on the NASDAQ Capital Market, Encorium Group Inc. has offices in 10 countries, managing clinical trials with their own employees. The Company’s corporate headquarters are in Wayne, Pennsylvania.

Encorium Group, Inc. provides their services to the pharmaceutical, biotechnology, and medical device industries. Their corporate mission is to provide their clients with high quality, full-service support for their biopharmaceutical and medical device development programs. They offer therapeutic expertise, experienced team management, and advanced technologies.

Encorium has drug and biologics development as well as clinical trial experience across a broad spectrum of therapeutic areas. These include infectious diseases, cardiovascular, vaccines, oncology, and diabetes endocrinology/metabolism. These also include gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women’s health

DrStockPick.com Stock Report!

Wednesday September 9, 2009

**************************************************************

ENCO,  Encorium Group Inc.

ENCO is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries.

ENCO reported the signing of approximately $8.7 million of new business contracts, including selection by a major pharmaceutical company for participation in a potential swine flu vaccineu vaccine program.

ENCO’s success in the vaccine field has been substantial, with revenues from vaccine trials increasing by 150% in 2009 versus 2008.

***********Advertisement***********

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

Friday, July 17, 2009

PennyOmega.com Stock Report!

**************************************************************

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world’s leading pharmaceutical companies, today announced that is has completed the previously announced sale of the Company’s U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano’s Stock Exchange. The purchase price was $2.7 million, comprised of $80,000 in cash as well as the assumption of $2.6 million in liabilities.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today it plans to